the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide
certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly,
BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the
amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources,
marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on
behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance,
internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based
allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel
devoted to OncoCyte’s operations or management. Management evaluates the appropriateness of the percentage allocations on
a periodic basis and believes that this basis for allocation is reasonable.
further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries
who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of
operations for the services performed in the periods presented.
November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information
including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise
of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes,
where applicable, to reflect the impact of the reverse stock split.
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including those related to the going concern assessments of OncoCyte financial
statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and
furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based
awards, debt or other equity instruments. Actual results could differ materially from those estimates.
the implementation of FASB’s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with
year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its
financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on
loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued,
which is referred to as the “look-forward period” as defined by ASU No. 2014-15. As part of this assessment, based
on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections,
estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and
its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary
or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs
and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to
execute them within the look-forward period in accordance with ASU No. 2014-15.
accounts for fair value measurements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards
Codification (“ASC”) 820, Fair Value Measurements (“ASC 820”). ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price)
in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize
the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two
are considered observable and the last unobservable, that may be used to measure fair value, which are the following: